COVID-19 – Wales – Shielding update and Q&A

Filmed on 23/06/2020. We are joined by Dr Steven Knapper, Senior Lecturer and Honorary Consultant Haematologist at the University Hospital Wales and Dr Nilima Parry - Jones consultant haematologist and MDT Chair Aneurin Bevan University Health Board.

23 June 2020

VIDEO RECORDED LIVE on 23/6/2020.

INFORMATION CORRECT AS OF THIS DATE.

Welcome to our 3rd set of webinars on shielding. This time we are talking specifically about the guidance for patients in Wales. We are joined by Dr Steven Knapper, Senior Lecturer and Honorary Consultant Haematologist at the University Hospital Wales and Dr Nilima Parry – Jones consultant haematologist and MDT Chair Aneurin Bevan University Health Board.

We will update and summarise Wales government shielding guidance and support provision; what this now means to patients and their families as shielding evolves.

Any questions, please email advocacy@leukaemiacare.org.uk.

Acute Megakaryoblastic Leukaemia (AMKL)

Acute megakaryoblastic leukaemia (AMKL) is a rare subtype of acute myeloid leukaemia (AML). It is more common in children than in adults. In children with Down syndrome, AMKL is the most common type of AML.